Pancreatic Cancer Research

ResearcherUniversity of DelawareActive in the last 2 years

Jordan Michael Winter

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-5200-6557; OpenAlex author ID A5048842063, A5067354904; NIH RePORTER profile ID 11146434. Sources: ClinicalTrials.gov.

Their work

Papers
69 (first author 5, last author 28)
Trials
2 (principal investigator on 2)
Grants
4
Labs led
4
Collaborators
135
Papers, trials and grants by year

2011: 1 paper · 2012: 5 papers · 2013: 3 papers, 1 trial · 2014: 2 papers, 1 grant · 2015: 3 papers · 2016: 6 papers · 2017: 2 papers · 2018: 9 papers, 1 trial · 2019: 1 paper · 2020: 5 papers · 2021: 9 papers · 2022: 10 papers · 2023: 5 papers · 2024: 3 papers, 1 grant · 2025: 1 paper · 2026: 4 papers, 2 grants

Papers 50 of 69

  1. Vitamin B3 derivatives support pancreatic cancer cell survival and chemotherapy resistance. Last author DOI 10.1016/j.canlet.2026.218334↗
  2. Cure probabilities of patients with pancreatic ductal adenocarcinoma in the United States: A Surveillance, Epidemiology, and End Results-based analysis. Last author DOI 10.1016/j.surg.2026.110223↗
  3. A ketogenic diet sensitizes pancreatic cancer to glutamine metabolism inhibitors. Last author DOI 10.1016/j.xcrm.2026.102770↗
  4. Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies. Last author DOI 10.1158/2767-9764.crc-25-0338↗
  5. Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence. Last author DOI 10.18632/oncotarget.28739↗
  6. MR Molecular Image Guided Treatment of Pancreatic Cancer with Targeted ECO/miR-200c Nanoparticles in Immunocompetent Mouse Tumor Models. Co-author DOI 10.1007/s11095-024-03762-7↗
  7. Understanding surgical attrition for "resectable" pancreatic cancer. Co-author DOI 10.1016/j.hpb.2023.11.008↗
  8. IDH1 Inhibition Potentiates Chemotherapy Efficacy in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-23-1895↗
  9. Disparities in guideline-compliant care for patients with pancreatic ductal adenocarcinoma at minority-versus non-minority-serving hospitals. Co-author DOI 10.1016/j.hpb.2023.07.903↗
  10. An analysis of time to treatment in patients with pancreatic adenocarcinoma. Last author DOI 10.1016/j.surg.2023.03.011↗
  11. Increased glucose availability sensitizes pancreatic cancer to chemotherapy. Last author DOI 10.1038/s41467-023-38921-8↗
  12. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  13. Trends in and Prognostic Significance of Time to Treatment in Pancreatic Cancer: A Population-Based Study. Last author DOI 10.1245/s10434-023-14221-9↗
  14. Prodromal depression and anxiety are associated with worse treatment compliance and survival among patients with pancreatic cancer. Last author DOI 10.1002/pon.5945↗
  15. Weight loss during neoadjuvant therapy for pancreatic cancer does not predict poor outcomes. Co-author DOI 10.1016/j.amjsurg.2021.10.001↗
  16. Combined multiagent chemotherapy and radiotherapy is associated with prolonged overall survival in patients with non-operatively managed stage II-III pancreati… Co-author DOI 10.1016/j.hpb.2021.08.938↗
  17. Multimodal therapy with or without irreversible electroporation for unresectable locally advanced pancreatic adenocarcinoma: a systematic review and meta-analy… Co-author DOI 10.1016/j.hpb.2021.12.014↗
  18. Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenocarcinoma. Co-author DOI 10.1016/j.hpb.2022.07.007↗
  19. Time to Neoadjuvant Chemotherapy Initiation Is not Associated With Survival in Pancreatic Cancer. Co-author DOI 10.1016/j.jss.2022.03.013↗
  20. A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems. Co-author DOI 10.1016/j.surg.2021.10.023↗
  21. Surgical techniques and tips for a reliable murine model of primary and metastatic pancreatic cancer Last author DOI 10.1101/2022.07.30.502136↗
  22. IDO1 Is a Therapeutic Target for Pancreatic Cancer-Associated Depression. Last author DOI 10.1158/1535-7163.mct-22-0055↗
  23. Liver Endothelium Microenvironment Promotes HER3-mediated Cell Growth in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.26502/jcsct.5079182↗
  24. The importance of time-to-adjuvant treatment on survival with pancreatic cancer: A systematic review and meta-analysis. Last author DOI 10.1002/cnr2.1390↗
  25. Neoadjuvant chemoradiation may be associated with improved pathologic response in pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2020.11.035↗
  26. Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis. Co-author DOI 10.1016/j.ejca.2021.01.004↗
  27. Pancreatic Cancer-Associated Diabetes is Clinically Distinguishable From Conventional Diabetes. Last author DOI 10.1016/j.jss.2020.12.015↗
  28. Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodene… Co-author DOI 10.1016/j.surg.2020.12.003↗
  29. Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer. Co-author DOI 10.1089/pancan.2021.0003↗
  30. Neoadjuvant Radiotherapy is Associated With Improved Pathologic Outcomes and Survival in Resected Stage II-III Pancreatic Adenocarcinoma Treated With Multiagen… Co-author DOI 10.1177/00031348211038581↗
  31. Elucidating the Causes of Improved Survival in Clinical Trials of Randomized Adjuvant Pancreatic Ductal Adenocarcinoma (PDAC). Last author DOI 10.1245/s10434-020-08859-y↗
  32. ASO Author Reflections: Prediagnosis Weight Loss: Early Detection and Postoperative Prognosis Among Patients with Pancreatic Cancer First author DOI 10.1245/s10434-021-09894-z↗
  33. Neoadjuvant chemotherapy is associated with improved survival in patients with left-sided pancreatic adenocarcinoma. Last author DOI 10.1002/jso.26196↗
  34. Optimizing cancer cure dialog: an analysis of pancreatic cancer patients' views regarding survival and cure. Last author DOI 10.1007/s00520-019-05214-0↗
  35. Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer. Co-author DOI 10.1136/esmoopen-2019-000668↗
  36. A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike? Last author DOI 10.18632/oncotarget.27727↗
  37. Magnetic Resonance Molecular Imaging of Extradomain B Fibronectin Improves Imaging of Pancreatic Cancer Tumor Xenografts. Co-author DOI 10.3389/fonc.2020.586727↗
  38. Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-18-3645↗
  39. Common Hepatic Artery Abutment or Encasement Is an Adverse Prognostic Factor in Patients with Borderline and Unresectable Pancreatic Cancer. Last author DOI 10.1007/s11605-017-3595-7↗
  40. A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. Co-author DOI 10.1016/j.jamcollsurg.2017.12.052↗
  41. Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer. Last author DOI 10.1080/15384047.2016.1210743↗
  42. Pancreatic Cancer-Associated Depression: A Case Report and Review of the Literature. Last author DOI 10.1097/mpa.0000000000001148↗
  43. Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Tria… Co-author DOI 10.1097/sla.0000000000002088↗
  44. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-18-0349↗
  45. Clinical Implications of Extensive Lymph Node Metastases for Resected Pancreatic Cancer. Last author DOI 10.1245/s10434-018-6763-4↗
  46. Metabolic Dependencies in Pancreatic Cancer. Last author DOI 10.3389/fonc.2018.00617↗
  47. Corrigendum: Metabolic Dependencies in Pancreatic Cancer. Last author DOI 10.3389/fonc.2018.00672↗
  48. Microscopic lymphovascular invasion is an independent predictor of survival in resected pancreatic ductal adenocarcinoma. Last author DOI 10.1002/jso.24723↗
  49. Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells. Last author DOI 10.1158/0008-5472.can-17-0015↗
  50. Pancreatic Cancer: A Review. First author DOI 10.1016/j.gtc.2016.04.003↗

Trials 2

  1. CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer Principal investigator NCT03374852↗
  2. Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-… Principal investigator NCT02414100↗

Grants 4

  1. Optimizing anti-wild-type IDH1 therapy in pancreatic cancer R01CA287672↗
  2. Leveraging high glucose to prevent pancreatic cancer progression R01CA305024↗
  3. Targeting pancreatic cancer's metabolic addiction to HuR R37CA227865↗
  4. MUC1-Targeted Nanotherapy for Pancreatic Cancer R21CA173605↗

Closest collaborators

The 25 strongest of 135 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jonathan Robert Brody · 24 shared papers, 2 shared grants, 2012–2026 · strength 4.34
  2. Jonathan J. Hue · 23 shared papers, 2020–2026 · strength 3.69
  3. John Brian Ammori · 18 shared papers, 2020–2024 · strength 2.72
  4. Jeffrey M. Hardacre · 18 shared papers, 2020–2024 · strength 2.72
  5. Lee Mayer Ocuin · 16 shared papers, 2020–2024 · strength 2.41
  6. Luke Daniel Rothermel · 16 shared papers, 2020–2026 · strength 2.41
  7. Kavin Sugumar · 13 shared papers, 2021–2025 · strength 2.03
  8. Mohamedraed Elshami · 8 shared papers, 2022–2026 · strength 1.64
  9. Mehrdad Zarei · 9 shared papers, 2022–2026 · strength 1.64
  10. Ali Vaziri Gohar · 11 shared papers, 2017–2026 · strength 1.62
  11. Charles J. Yeo · 22 shared papers, 2012–2021 · strength 1.45
  12. Omid Hajihassani · 8 shared papers, 2022–2026 · strength 1.33
  13. David Lawrence Bajor · 7 shared papers, 2020–2023 · strength 0.95
  14. Erryk Katayama · 6 shared papers, 2020–2026 · strength 0.95
  15. Sarah Coseo Markt · 5 shared papers, 2021–2022 · strength 0.78
  16. Mahsa Zarei · 7 shared papers, 2016–2023 · strength 0.59
  17. Harish Lavu · 6 shared papers, 2017–2021 · strength 0.59
  18. Richard S. Hoehn · 3 shared papers, 2022–2024 · strength 0.53
  19. Andre Alabd · 3 shared papers, 2021–2025 · strength 0.51
  20. Faith Nakazzi · 2 shared papers, 2024–2026 · strength 0.48
  21. Moeez Ghani Rathore · 3 shared papers, 2022–2026 · strength 0.47
  22. Shreya Gupta · 2 shared papers, 2023 · strength 0.36
  23. Hanna H. Kakish · 2 shared papers, 2022–2024 · strength 0.35
  24. Saswati N. Chand · 6 shared papers, 2013–2019 · strength 0.34
  25. Avinoam Nevler · 4 shared papers, 2017–2020 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.